JUL 0 7 2003

IN THE UNITED STATES PATENT AND TRADMARK OFFICE

Applicant: Henkin, et al.

Serial No.: 09/833,196

Filed: April 11, 2001

For: PEPTIDE ANTIANGIOGENIC DRUG

Case No.: 6356.US.P4

Group Art No.: 1653

Examiner: Lukton, David

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450 on:

Date of Deposit: July 2, 2003

Tanya Parent

RECEIVED

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

JUL 1 1 2003

RESPONSE TO RESTRICTION REQUIREMENT, ELECTION OF SPECIES and AMENDMENT

Dear Sir:

The following is submitted in response to the Office Action mailed 04/17/2003. The due date for response to the Action has been extended three months to 7/17/2003.

Response to Restriction Requirement

In response to the restriction requirement mailed 17 April 2003, Applicants hereby elect Group 1, Claims 1-8, 10 and 12. As indicated on the enclosed sheet entitled "Amendments to the Claims", Applicants have amended the claims to indicate the withdrawal of Claims 9 and 11 from further consideration.

Response to Election Requirement

In response the election requirement mailed 17 April 2003, Applicants hereby provisionally elect the compound of Example 380, page 172, for examination purposes. For the convenience of the examiner, the amino acid sequence of Example 380 is reproduced below.

A_0	A ₁	A ₂	A ₃	A ₄	A ₅	A ₆	A ₇	A ₈	A9	A ₁₀
N-Ac	Sar	Gly	Val	D-Ile	alloThr	Pro	Ile	Arg	Pro	NHCH ₂ CH ₃

Amendments to the Claims

Please amend the above-identified application as indicated on the enclosed sheets.